1. Scrip
  2. >>New Products

Biohaven’s Q3 Nurtec ODT Sales Indicate Gains Across Multiple Launch Parameters

Growth Seen In First Full Quarter With Dual Migraine Indications

 
• By Mandy Jackson

The company pre-announced $136m in third quarter sales, beating analyst consensus and signaling both increased oral CGRP inhibitor market share and improved per-prescription net revenue.

Blue Arrows Rising up in wood blocks
Nurtec ODT revenue grew from $43.8m in Q1 to $93m in Q2 and now $136m in Q3 • Source: Alamy

Biohaven Pharmaceutical Holding Company Ltd.. said on 5 October that its migraine drug Nurtec ODT (rimegepant) generated $136m in third quarter net product revenue, which represents a 46% jump from $96m in the second quarter. The Q3 number, announced a month ahead of Biohaven’s audited quarterly earnings report, indicate that the company’s aggressive sales push is paying off across multiple launch parameters.

New Haven, CT-based Biohaven said its drug – which was approved last year in the US as an acute treatment for migraine attacks and this year as a migraine prevention therapy – is now the leader among oral CGRP inhibitors, accounting for about 61% of new-to-brand prescriptions

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Pipeline Watch: Eight Approvals And Nineteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 
• By Andrew McConaghie

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

More from Scrip

Apnimed’s AD109 Could Be A Wake-Up Call For Sleep Apnea Market

 
• By Joseph Haas

The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.

First Blood-Based Test Cleared For Alzheimer’s Boosts Anti-Amyloid Drugs

 
• By Mandy Jackson

The US FDA approval of Fujirebio’s Lumipulse should boost access to medicines like Eisai’s Leqembi and Lilly’s Kisunla; the firms are praising patients’ access to earlier diagnoses.

Regeneron Sees 23andMe Buy As Complement To Genetics Platform

 
• By Alaric DeArment

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.